Press Release CEO Perspective: We are ClearNote Health – Allow Us to Re-Introduce Ourselves ClearNote Health December 21, 2022
Press Release Bluestar Genomics Advances to Commercial Phase, Rebrands as ClearNote Health ClearNote Health December 21, 2022
Press Release Bluestar Genomics Initiates One of the Largest Clinical Trials for Early Detection of Pancreatic Cancer ClearNote Health December 6, 2022
Press Release Bluestar Genomics Presents Positive Results from Validation Study in Pancreatic Cancer Detection at American Pancreatic Association (APA) Annual Meeting ClearNote Health November 2, 2022
Press Release Bluestar Genomics Receives CAP Accreditation for its Clinical Laboratory ClearNote Health October 10, 2022
Press Release Bluestar Genomics Presents Data on New Applications of its Epigenomic Cancer Detection Platform ClearNote Health September 12, 2022
Press Release Bluestar Genomics Receives CLIA Certification for its Clinical Laboratory ClearNote Health June 6, 2022
Press Release Bluestar Genomics to Participate in the Goldman Sachs 2022 Healthcare Disruption Conference ClearNote Health March 30, 2022
Press Release Bluestar Genomics Presents Positive Results of its Pancreatic Cancer Test Performance Evaluation at 2022 ASCO GI Cancers Symposium ClearNote Health January 20, 2022
Press Release Bluestar Genomics Appoints David Mullarkey Chief Executive Officer ClearNote Health January 10, 2022
